




PHARMACEUTICAL 2019

NeuroBo Pharmaceuticals Inc.
Rank 291 of 363





PHARMACEUTICAL 2019

NeuroBo Pharmaceuticals Inc.
Rank 291 of 363

The relative strengths and weaknesses of NeuroBo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NeuroBo Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 30% points. The greatest weakness of NeuroBo Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is -65%, being 102% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	19,686
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,919
Liabilities, Non-Current	1.0
Other Assets	8.0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-832
Other Revenues	0
Property and Equipment	0
Research and Development	14,312
Selling, General and Administrative Expense	8,493

Output Variable	Value in 1000 USD
Assets	19,694
Liabilities	11,920
Expenses	22,805
Revenues	0
Stockholders Equity	7,774
Net Income	-23,637
Comprehensive Net Income	-23,637
Economic Capital Ratio	-65%